

FRONTIERS IN CARDIOVASCULAR BIOLOGY

Third Meeting of the ESC Council on Basic Cardiovascular Science

FCVB 2014

BARCELONA

4-6 JULY

www.escardio.org/FCVB

POST CONGRESS REPORT

1 | Page

TABLE OF CONTENT

| | |
|---|-----------|
| 1. GENERAL INFORMATION | 3 |
| 1.1 INTRODUCTION..... | 3 |
| 1.2 HISTORY | 3 |
| 1.3 COMMITTEES | 4 |
| 1.4 CONGRESS DATES AND LOCATION | 5 |
| 1.5 VENUE | 5 |
| 1.6 TIMETABLE | 6 |
| 2. SCIENTIFIC PROGRAMME..... | 7 |
| 3. REGISTRATION & ATTENDANCE | 20 |
| 3.1 TOTAL ATTENDANCE..... | 20 |
| 3.2 BY COUNTRY..... | 20 |
| 3.2.1 <i>Top 10 Countries</i> | 22 |
| 3.3 BY REGION | 22 |
| 4.1 EXHIBITORS..... | 23 |
| 4.2 EXHIBITION | 23 |
| 4.3 SATELLITE SYMPOSIA | 23 |
| 4.4 SPONSORSHIP & ADVERTISING | 23 |
| 5. MARKETING SURVEY | 25 |
| 5.1 FCVB 2014 ATTENDEES POST CONGRESS SURVEY ANALYSIS: | 25 |
| 5.1.1 DELEGATES' PROFILE..... | 25 |
| 5.1.2 DELEGATES DEMOGRAPHICS | 25 |
| 5.1.3 DELEGATES' BEHAVIOUR..... | 25 |
| 5.1.4 DELEGATES' AWARENESS OF THE COUNCIL'S ACTIVITIES | 27 |
| 5.1.5 DELEGATES' LEVEL OF SATISFACTION | 28 |
| 5.2 POST CONGRESS SURVEY TO NON FCVB ATTENDEES ANALYSIS:..... | 30 |

1. GENERAL INFORMATION

1.1 INTRODUCTION

Frontiers in CardioVascular Biology 2014 was the Third Meeting of the Council on Basic Cardiovascular Science (CBCS) of the European Society of Cardiology (ESC). The Council is composed of representatives from the ESC "basic" Working Groups and from non-ESC "basic" sister organisations.

8 ESC Working Groups:

Atherosclerosis and Vascular Biology
Cardiac Cellular Electrophysiology
Cardiovascular Pharmacology and Drug Therapy
Cellular Biology of the Heart
Coronary Pathophysiology and Microcirculation
Development, Anatomy and Pathology
Myocardial Function
Thrombosis

And

5 Sister Societies:

Association for European CardioVascular Pathology (AECVP)
European Vascular Biology Organisation (EVBO)
European Council for Cardiovascular Research (ECCR)
European Society for Microcirculation (ESM)
International Society for Heart Research European Section (ISHR-ES)

Its third edition in Barcelona continued the ideals of the two previous meetings to bring the best and newest science to the cardiovascular arena. Within a wide-ranging programme, themes of Bioimaging, Degeneration and Regeneration, and Inflammation were highlighted. Invited speaker presentations, shorter talks selected from submitted abstracts, ensuring both the most recent data and strong involvement of younger speakers. Poster sessions were central in both position and timing.

With travel bursaries and low early career registration fees, this was a meeting ideal for students and trainees.

1.2 HISTORY

FCVB 2010

16-19 July 2010

Berlin, Charité University Campus

FCVB 2012

30 March – 1 April 2012

London, Imperial College

FCVB 2014

4 – 6 July 2014

Barcelona, Palau de Congressos de Catalunya

1.3 COMMITTEES

Core Scientific Programme Committee

Prof. Lina Badimon (ES) - Chairperson
Prof. Barbara Casadei (GB)
Prof. Sian Harding (GB)
Prof. Jeremy Pearson (GB)
Prof. Axel Pries (DE)
Prof. Karin Sipido (BE)

Programme Committee - WG and Sister Societies Coordinators

Prof. Christian Weber (DE)
WG Atherosclerosis and Vascular Biology
Prof. Godfrey Smith (GB)
WG Cardiac Cellular Electrophysiology
Prof. Keld Kjeldsen (DK)
WG Cardiovascular Pharmacology and Drug Therapy
Dr. Derek Hausenloy (GB)
WG Cellular Biology of the Heart
Prof. Cor De Wit (DE)
WG Coronary Pathophysiology and Microcirculation
Prof. Diego Franco (ES)
WG Development, Anatomy and Pathology
Prof. Jean-Luc Balligand (BE)
WG Myocardial Function

Prof. Agneta Siegbahn (SE)
WG Thrombosis
Assoc Prof. Annalisa Angelini (IT)
Association for European Cardiovascular Pathology (AECVP)
Prof. Josef Dulak (PL)
European Vascular Biology Organisation (EVBO)
Prof. Jo de Mey (DK)
European Council for Cardiovascular Research (ECCR)
Prof. Giovanni Mann (GB)
European Society for Microcirculation (ESM)
Prof. Thomas Eschenhagen (DE)
International Society for Heart Research - European Section (ISHR-ES)

International Scientific Advisory Committee

Prof. Kari Alitalo (FI)
Prof. Juan Jose Badimon (US)
Dr. David Bennett (GB)
Prof. Raffaele de Caterina (IT)
Prof. Stephanie Dimmeler (DE)
Dr. Valentin Fuster (US)
Prof. Anders Hamsten (SE)
Prof. Goran K Hansson (SE)
Prof. Gerd Heusch (DE)
Prof. Steve Lentz (US)
Prof. Thomas F Luscher (CH)
Prof. Nigel Mackman (US)
Prof. Ursula Ravens (DE)

Local Scientific Advisory Board


Prof. Antoni Bayes Genís
Prof. Josep Brugada
Prof. Juan Cinca
Prof. Javier Diez
Prof. Francisco Fernández-Avilés
Prof. Diego Franco
Prof. David García-Dorado
Prof. José Ramón González-Juanatey
Dr. Borja Ibañez
Prof. Jose Lopez-Miranda
Dr. Francisco Marin
Dr. Jaume Marrugat
Dr. Felipe Prosper
Prof. Juan Tamargo
Dr. José Tuñón
Dr. Gemma Vilahur
Dr. Jose Luis Zamorano

1.4 CONGRESS DATES AND LOCATION

4-6 July 2014
Barcelona, Spain

1.5 VENUE

Palau de Congressos de Catalunya
Avenida Diagonal, 661-671
08208 Barcelona – Spain
www.pcongresos.com



Room capacities

FCVB Room 1 – 700
FCVB Room 2 – 350
FCVB Room 3 – 150

1.6 TIMETABLE

| THURSDAY 3rd JULY | | | FRIDAY 4th JULY | | | SATURDAY 5th JULY | | | SUNDAY 6th JULY | | |
|-------------------|--|-------|-----------------|--|-------|-------------------|--|-------|-----------------|--|-------|
| 08:00 | | 08:00 | 08:00 | | 08:00 | 08:00 | | 08:00 | 08:00 | | 08:00 |
| 08:30 | ISHR | 08:30 | | | 08:30 | | | 08:30 | | | 08:30 |
| 09:00 | Registration | 09:00 | | | 09:00 | | | 09:00 | | | 09:00 |
| 09:30 | ISHR SESSION 1 | 09:30 | | | 09:30 | | | 09:30 | | | 09:30 |
| 10:00 | | 10:00 | | | 10:00 | | | 10:00 | | | 10:00 |
| 10:30 | | 10:30 | | | 10:30 | | | 10:30 | | | 10:30 |
| 11:00 | ISHR BREAK | 11:00 | | | 11:00 | | | 11:00 | | | 11:00 |
| 11:30 | THE WORKING GROUP ON ATHEROSCLEROSIS AND VASCULAR BIOLOGY SYMPOSIUM ON "CIRCULATING BIOMARKERS IN ATHEROSCLEROSIS" | 11:30 | | | 11:30 | | | 11:30 | | | 11:30 |
| 12:00 | | 12:00 | | | 12:00 | | | 12:00 | | | 12:00 |
| 12:30 | | 12:30 | | | 12:30 | | | 12:30 | | | 12:30 |
| 13:00 | | 13:00 | | | 13:00 | | | 13:00 | | | 13:00 |
| 13:30 | | 13:30 | | | 13:30 | | | 13:30 | | | 13:30 |
| 14:00 | | 14:00 | | | 14:00 | | | 14:00 | | | 14:00 |
| 14:30 | | 14:30 | | | 14:30 | | | 14:30 | | | 14:30 |
| 15:00 | | 15:00 | | | 15:00 | | | 15:00 | | | 15:00 |
| 15:30 | | 15:30 | | | 15:30 | | | 15:30 | | | 15:30 |
| 16:00 | | 16:00 | | | 16:00 | | | 16:00 | | | 16:00 |
| 16:30 | | 16:30 | | | 16:30 | | | 16:30 | | | 16:30 |
| 17:00 | | 17:00 | | | 17:00 | | | 17:00 | | | 17:00 |
| 17:30 | | 17:30 | | | 17:30 | | | 17:30 | | | 17:30 |
| 18:00 | | 18:00 | | | 18:00 | | | 18:00 | | | 18:00 |
| 18:30 | | 18:30 | | | 18:30 | | | 18:30 | | | 18:30 |
| 19:00 | | 19:00 | | | 19:00 | | | 19:00 | | | 19:00 |
| 19:30 | | 19:30 | | | 19:30 | | | 19:30 | | | 19:30 |
| 20:00 | | 20:00 | | | 20:00 | | | 20:00 | | | 20:00 |
| 20:30 | | 20:30 | | | 20:30 | | | 20:30 | | | 20:30 |
| 21:00 | | 21:00 | | | 21:00 | | | 21:00 | | | 21:00 |

2. Scientific programme

1. General Information

3 Lecture rooms

39 Pre-arranged sessions

- 1 Abstract Session
- 21 Featured Symposium
- 5 Main Session
- 3 Poster Session
- 1 Satellite Symposium
- 3 Special Event
- 2 Special Session
- 3 Symposium

685 Abstracts Received

657 Abstracts Accepted (94 %)

4 Abstract-based sessions

- 1 YIA Session
- 3 Poster Session

119 Faculty Members

196 Roles

- 58 roles of Chairperson
- 87 roles of Speaker
- 51 roles of Other

5 Special Sessions / Special Events

- Scientists of Tomorrow: new pathway for basic research
- ISHR-ES Awards and Lecture
- Welcome - Opening Ceremony
- Inaugural Session
- Awards and Closing Ceremony

2. FACULTY RELATED REPORTS

2.1- Overview Industry & ESC Session

| Type of sessions | Roles held |
|------------------|------------|
| Industry | 4 |
| Total | 4 |
| FCVB Programme | |
| Abstract | 47 |
| Pre-arranged | 149 |
| Total | 196 |

2.3 – FCVB 2014 Session

Number of Roles held in the FCVB Programme

196 roles distributed as shown below

| Faculty roles distributed for FCVB programme | Total |
|--|-------|
| Chairperson | 58 |
| Discussant | 41 |
| Judge Abstract | 10 |
| Speaker | 87 |
| Grand Total | 196 |

Number of Faculty invited for FCVB Programme

119 Faculty members involved in the FCVB 2014 Programme

This number only includes INVITED Faculty

Faculty Gender Overview

| Faculty Gender | Total |
|----------------|-------|
| Female | 33 |
| Male | 86 |
| Total | 119 |

ORIGIN of the Faculty

By region

| Region | Total |
|---------------|-------|
| ESC | 106 |
| North America | 13 |
| Total | 119 |

By country

| Country | Total |
|---------|-------|
| Austria | 5 |
| Belgium | 3 |

| | |
|--------------------------|-----|
| France | 6 |
| Germany | 17 |
| Hungary | 2 |
| Israel | 1 |
| Italy | 9 |
| Luxembourg | 1 |
| Netherlands | 12 |
| Norway | 2 |
| Poland | 1 |
| Spain | 20 |
| Sweden | 1 |
| Switzerland | 2 |
| United Kingdom | 24 |
| United States of America | 13 |
| Grand Total | 119 |

2.4 - Comparison report 2012 & 2014

Activities

| Faculty roles distributed for FCVB programme | 2012 | 2014 |
|---|-------------|-------------|
| Chairperson | 81 | 58 |
| Discussant | - | 41 |
| Judge Abstract | 85 | 10 |
| Speaker | 87 | 87 |
| Grand Total | 253 | 196 |

Role distribution

| Total | 2012 | 2014 |
|---------------|-------------|-------------|
| 1 roles | 51 | 77 |
| 2 roles | 63 | 25 |
| 3 roles | 13 | 8 |
| 4 roles | 8 | 6 |
| 5 roles | 1 | |
| 6 roles | | 6 |
| Total faculty | 136 | 119 |

Top Country Representation

*Host country 2014

** Host country 2012

| Country | FCVB 2012 | FCVB 2014 | Country | FCVB 2012 | FCVB 2014 |
|--------------------------|--------------|--------------|-------------|--------------|--------------|
| United Kingdom** | 43 | 24 | Hungary | 1 | 2 |
| Spain* | 4 | 20 | Norway | 1 | 2 |
| Germany | 20 | 17 | Switzerland | 1 | 2 |
| United States of America | 9 | 13 | Israel | 1 | 1 |
| Netherlands | 15 | 12 | Luxembourg | | 1 |
| Italy | 11 | 9 | Poland | | 1 |
| France | 11 | 6 | Sweden | 6 | 1 |
| Austria | 3 | 5 | Canada | 1 | |
| Belgium | 5 | 3 | Denmark | 4 | |

Faculty by Country (Countries in Alpha order)

| Country | FCVB 2012 | FCVB 2014 |
|--------------------------|--------------|--------------|
| Austria | 3 | 5 |
| Belgium | 5 | 3 |
| Canada | 1 | |
| Denmark | 4 | |
| France | 11 | 6 |
| Germany | 20 | 17 |
| Hungary | 1 | 2 |
| Israel | 1 | 1 |
| Italy | 11 | 9 |
| Luxembourg | | 1 |
| Netherlands | 15 | 12 |
| Norway | 1 | 2 |
| Poland | | 1 |
| Spain* | 4 | 20 |
| Sweden | 6 | 1 |
| Switzerland | 1 | 2 |
| United Kingdom** | 43 | 24 |
| United States of America | 9 | 13 |

Faculty By regions

| Region | FCVB 2012 | FCVB 2014 |
|---------------|--------------|--------------|
| ESC | 126 | 106 |
| North America | 10 | 13 |
| Grand Total | 136 | 119 |

3. SESSION RELATED REPORT

3.1-All sessions

| Process Type | Type | Total |
|-----------------|------------------------------------|-------|
| Abstract | Young Investigator Award abstracts | 1 |
| | Poster Session | 3 |
| | Total abstract sessions | 4 |
| | Featured Symposium | 21 |
| | Main Session | 5 |
| | Special Event | 3 |
| | Special Session | 2 |
| | Symposium | 3 |
| | Total Pre-arranged sessions | 34 |
| Industry | Satellite Symposium | 1 |
| | Grand Total | 39 |

3.2- FCVB 2014 sessions

This charts does not include poster, special event and Industry sessions

| Process Type | Type | Total |
|---------------------|------------------------------------|-------|
| Abstract | Young Investigator Award abstracts | 1 |
| | Total abstract session | 1 |
| Pre-arranged | Featured Symposium | 21 |
| | Main Session | 5 |
| | Special Session | 2 |
| | Symposium | 3 |
| | Total Pre-arranged sessions | 31 |
| | Grand Total | 32 |

Session by Topic

| Topic | Total |
|---|-------|
| 00.00 - Unknown | 7 |
| 01.00 - Developmental biology | 2 |
| 02.00 - Genetics, Epigenetics and Genomics | 2 |
| 03.00 - Growth/death, Regeneration and Stem cells | 3 |
| 04.00 - Signaling | 1 |
| 05.00 - Ion channels and electrophysiology | 1 |
| 06.00 - Excitation-contraction coupling, Cardiomyopathy | 1 |
| 07.00 - Metabolism, Oxygen, Ischaemia and Protection | 1 |
| 08.00 - Circulation, Vascular biology | 6 |
| 09.00 - Lipids, Atherosclerosis | 3 |
| 10.00 - Cytoskeleton | 1 |
| 11.00 - Integrative mechanisms, Novel diagnostic and Therapeutic approaches | 4 |
| Grand Total | 32 |

Sessions by lecture room by day

| Room location | 04/07/2014 | 05/07/2014 | 06/07/2014 | Total by room |
|---------------------|------------|------------|------------|---------------|
| FCVB Room 1 | 4 | 5 | 5 | 14 |
| FCVB Room 2 | 3 | 3 | 3 | 9 |
| FCVB Room 3 | 3 | 3 | 3 | 9 |
| Total by day | 10 | 11 | 11 | 32 |

3.4- Session comparison FCVB 2012 – 2014

Number of sessions by type - ALL sessions

| Process Type | Type | 2012 | 2014 |
|-----------------|------------------------------------|------|------|
| Abstract | Abstract Session | 1 | |
| | Young Investigator Award abstracts | 1 | 1 |
| | Poster Session | 3 | 3 |
| | Total abstract sessions | 5 | 4 |
| | Featured Symposium | | 21 |
| | Main Session | 5 | 5 |
| | Special Event | 3 | 3 |
| | Special Session | 2 | 2 |
| | Symposium | 26 | 3 |
| | Work shop | 1 | |
| | Total Pre-arranged sessions | 37 | 34 |
| Industry | Satellite Symposium | | 1 |
| Total | | 42 | 39 |

These charts below does not include poster, special events and satellite sessions
Number of Sessions by type

| Process Type | Type | 2012 | 2014 |
|---------------------|------------------------------------|------|------|
| Abstract | Abstract Session | 1 | |
| | Young Investigator Award abstracts | 1 | 1 |
| | Total abstract sessions | 2 | 1 |
| Pre arranged | Featured Symposium | | 21 |
| | Main Session | 5 | 5 |
| | Special Session | 2 | 2 |
| | Symposium | 26 | 3 |
| | Total Pre-arranged sessions | 33 | 31 |
| Total | | 35 | 32 |

Number of Sessions per day

| Day | 2012 | 2014 |
|-------------|------|------|
| Friday | 10 | 10 |
| Saturday | 12 | 11 |
| Sunday | 11 | 11 |
| Grand Total | 33 | 32 |

Number of sessions by topic

| Topic | 2012 | 2014 |
|---|------|------|
| 00.00 - General | 3 | 7 |
| 01.00 - Developmental biology | 5 | 2 |
| 02.00 - Genetics, Epigenetics and Genomics | 1 | 2 |
| 03.00 - Growth/death, Regeneration and Stem cells | 1 | 3 |
| 04.00 - Signaling | 2 | 1 |
| 05.00 - Ion channels and Electrophysiology | 2 | 1 |
| 06.00 - Excitation-contraction coupling, Cardiomyopathy | 4 | 1 |
| 07.00 - Metabolism, Oxygen, Ischaemia and Protection | 2 | 1 |
| 08.00 - Circulation, Vascular biology | 8 | 6 |
| 09.00 - Lipids, Atherosclerosis | 2 | 3 |
| 10.00 - Cytoskeleton | 2 | 1 |
| 11.00 - Integrative mechanisms, Novel diagnostic and Therapeutic approaches | 1 | 4 |
| Grand Total | 33 | 32 |

4. SESSIONS OCCUPANCY REPORT

4.1 Occupancy FCVB scientific sessions only

Attendance per time slot per day

| Session date | Session Start Time | FCVB Room 1 700 Pax | FCVB Room 2 350 Pax | FCVB Room 3 200 Pax | Grand Total |
|--------------|--------------------|------------------------|------------------------|------------------------|-------------|
| Friday | 10:00 | 295 | | | 295 |
| | 11:00 | 150 | 100 | 245 | 495 |
| | 14:30 | 200 | 115 | 100 | 415 |
| | 16:30 | 150 | 110 | 80 | 340 |
| Total | | 795 | 325 | 425 | 1545 |
| Saturday | 09:00 | 140 | 100 | 55 | 295 |
| | 10:45 | 450 | | | 450 |
| | 13:30 | 90 | 130 | 170 | 390 |
| | 15:30 | 75 | 135 | | 210 |
| | 17:15 | 300 | | | 300 |
| Total | | 1055 | 365 | 225 | 1645 |
| Sunday | 09:00 | 100 | 40 | 45 | 185 |
| | 10:45 | 250 | | | 250 |
| | 13:30 | 80 | 85 | 50 | 215 |

| | | | | | |
|--------------------|-------|-------------|------------|------------|-------------|
| | 15:30 | 70 | 140 | 55 | 265 |
| | 16:45 | 140 | | | 140 |
| Total | | 640 | 265 | 150 | 1055 |
| Grand Total | | 2490 | 955 | 800 | 4245 |

Session by occupancy

| Occupancy | Total |
|-----------|-------|
| 100-200 | 11 |
| 200-300 | 4 |
| 400-500 | 1 |
| 50-100 | 13 |
| Less 50 | 2 |

List of top attended sessions

| Session Title | Type | Main Topic | Occupancy @ Peak | Max Occup % | Room Capacity | Session Start Time |
|---|--------------------|---|------------------|-------------|---------------|---------------------|
| Keynote Lecture - iPSCs for cardiovascular diseases | Main Session | 00.00 - Unknown | 450 | 64% | 700 | 05/07/2014 10:45:00 |
| Keynote Lecture - Telomeres and disease | Main Session | 00.00 - Unknown | 300 | 43% | 700 | 05/07/2014 17:15:00 |
| Keynote Lecture - The two pathways of translational cardiovascular research: the next decade | Main Session | 00.00 - Unknown | 295 | 42% | 700 | 04/07/2014 10:00:00 |
| Keynote Lecture - Protective autoimmunity limits atherosclerosis | Main Session | 00.00 - Unknown | 250 | 36% | 700 | 06/07/2014 10:45:00 |
| Cell death: not always a bad thing | Featured Symposium | 03.00 - Growth/death, Regeneration and Stem cells | 245 | 123% | 200 | 04/07/2014 11:00:00 |
| Scientists of Tomorrow: new pathway for basic research | Special Session | 07.00 - Metabolism, Oxygen, Ischaemia and Protection | 200 | 29% | 700 | 04/07/2014 14:30:00 |
| Mechanisms in cardiac fibrosis | Featured Symposium | 10.00 - Cytoskeleton | 170 | 85% | 200 | 05/07/2014 13:30:00 |
| Epigenetics in cardiac development and disease | Featured Symposium | 01.00 - Developmental biology | 150 | 21% | 700 | 04/07/2014 11:00:00 |
| Longevity | Featured Symposium | 11.00 - Integrative mechanisms, Novel diagnostic and Therapeutic approaches | 150 | 21% | 700 | 04/07/2014 16:30:00 |
| Keynote Lecture - Molecular therapies for inherited arrhythmias | Main Session | 00.00 - Unknown | 140 | 20% | 700 | 06/07/2014 16:45:00 |
| Frontiers in iPS technology | Featured Symposium | 03.00 - Growth/death, Regeneration and Stem cells | 140 | 20% | 700 | 05/07/2014 09:00:00 |
| Heart repair with or without stem cells | Symposium | 03.00 - Growth/death, Regeneration and Stem cells | 140 | 40% | 350 | 06/07/2014 15:30:00 |

List of least attended sessions

| Session Title | Type | Main Topic | Occupancy @ Peak | Max Occup % | Room Capacity | Session Start Time |
|---|--------------------|---|------------------|-------------|---------------|---------------------|
| Antiplatelet treatment and cardioprotection against myocardial reperfusion injury. | Featured Symposium | 08.00 - Circulation, Vascular biology | 40 | 11% | 350 | 06/07/2014 09:00:00 |
| Biology and pharmacology of novel targets for antiplatelet therapy | Featured Symposium | 08.00 - Circulation, Vascular biology | 45 | 23% | 200 | 06/07/2014 09:00:00 |
| Evolution of the heart – Lessons for the future | Featured Symposium | 01.00 - Developmental biology | 50 | 25% | 200 | 06/07/2014 13:30:00 |
| New paradigms in arrhythmias | Featured Symposium | 05.00 - Ion channels and electrophysiology | 55 | 28% | 200 | 05/07/2014 09:00:00 |
| Cell phones: vascular communication via Connexins | Symposium | 11.00 - Integrative mechanisms, Novel diagnostic and Therapeutic approaches | 55 | 28% | 200 | 06/07/2014 15:30:00 |
| Metabolomics in cardiovascular research | Symposium | 11.00 - Integrative mechanisms, Novel diagnostic and Therapeutic approaches | 70 | 10% | 700 | 06/07/2014 15:30:00 |
| Vascular cell pathobiology | Featured Symposium | 08.00 - Circulation, Vascular biology | 75 | 11% | 700 | 05/07/2014 15:30:00 |
| RNAs in cardiovascular medicine | Featured Symposium | 02.00 - Genetics, Epigenetics and Genomics | 80 | 11% | 700 | 06/07/2014 13:30:00 |
| A super-resolution view of cardiac EC coupling | Featured Symposium | 06.00 - Excitation-contraction coupling, Cardiomyopathy | 80 | 40% | 200 | 04/07/2014 16:30:00 |
| Tissue factor and biology | Featured Symposium | 08.00 - Circulation, Vascular biology | 85 | 24% | 350 | 06/07/2014 13:30:00 |

5. Abstracts related report

Overview by all status – comparison with previous years

| | 2012 | 2014 |
|--------------------------------------|------|------|
| Submitted | 625 | 698 |
| Not validated & Withdrawn | 11 | 13 |
| Accepted | 565 | 657 |
| Rejected | 49 | 28 |
| Withdrawn after acceptance | 35 | 56 |
| Acceptance rate | 92% | 94% |
| No show | 53 | 79 |

Composition of the sessions

Sessions assignment: number of abstract for each session type

| Session Type | 2012 | 2014 |
|------------------------------|------|------|
| YIA Abstract Session | 6 | 6 |
| Oral abstract session | 6 | |
| Featured Presentation | 42 | 63 |
| Poster Presentation | 511 | 588 |
| Grand Total | 565 | 657 |

By Topic

| Topic | Accepted | Accepted Withdrawn | No show | Presented |
|---|----------|--------------------|---------|-----------|
| Ischemia / reperfusion | 70 | 6 | 12 | 52 |
| Electrophysiology / Arrhythmias | 37 | 2 | 5 | 30 |
| Atherosclerosis | 35 | 6 | 3 | 26 |
| Endothelium | 32 | 2 | 3 | 27 |
| Cardiomyopathies / Mechanisms | 29 | 1 | 2 | 26 |
| Stem cells and cell therapy | 28 | 4 | 2 | 22 |
| Microcirculation | 26 | 3 | 7 | 16 |
| Therapeutic approaches / Nanomedicine / Gene therapy | 24 | 2 | 2 | 20 |
| Gene analysis | 20 | 2 | 4 | 14 |
| Non-coding RNA | 20 | 3 | 1 | 16 |
| Cytokines / Inflammation | 20 | 2 | 1 | 17 |
| Mitochondria | 18 | 2 | 2 | 14 |
| Inflammation / Leucocytes | 17 | 1 | 2 | 14 |
| Smooth muscle | 17 | 2 | 1 | 14 |
| Biomarkers | 16 | 2 | 4 | 10 |
| Cell death / apoptosis / autophagy | 15 | | 2 | 13 |
| Diagnostic approaches / Molecular imaging | 14 | | 6 | 8 |
| Lipids | 14 | | 3 | 11 |
| Angiogenesis | 13 | 1 | 2 | 10 |
| Calcium fluxes | 13 | | 2 | 11 |
| Transcriptional control | 13 | | 1 | 12 |
| Cell differentiation / Proliferation | 10 | 1 | 1 | 8 |
| Ion channels / Ion exchangers and pumps | 10 | | 1 | 9 |
| Thrombosis and platelets | 9 | 3 | | 6 |
| Fibroblasts / Fibrosis / Matrix | 9 | 1 | | 8 |
| Hibernation / preconditioning / stunning | 9 | | 1 | 8 |
| Hypertrophy, cell cycle and apoptosis | 9 | 1 | | 8 |
| Neurohormones | 9 | 1 | | 8 |
| Pathology | 9 | | 1 | 8 |
| Growth factors | 9 | | | 9 |
| Nitric oxide / reactive oxygen species | 9 | | | 9 |
| Haemostasis | 8 | 1 | 2 | 5 |
| Animal models | 7 | 2 | | 5 |

| | | | | |
|--|-----|----|----|-----|
| Energetics | 7 | 1 | 1 | 5 |
| Contractile apparatus | 7 | | | 7 |
| Proteomics / metabolomics / lipidomics / glycomics | 6 | | 2 | 4 |
| Aging | 6 | | 1 | 5 |
| Tissue engineering | 6 | | | 6 |
| Morphogenetic mechanisms | 5 | | 1 | 4 |
| Computer modelling / Bioinformatics | 4 | 2 | | 2 |
| Oxygen sensing | 4 | 1 | 1 | 2 |
| Control mechanisms | 4 | | | 4 |
| Mechanotransduction | 3 | 1 | | 2 |
| Cytoskeleton / Cytoarchitecture | 3 | | | 3 |
| Developmental genetics | 2 | | | 2 |
| Gender | 2 | | | 2 |
| Grand Total | 657 | 56 | 79 | 522 |


Abstracts by country

| Country | Accepted | Accepted Withdrawn | No show | Presented |
|-----------------------------|----------|--------------------|---------|-----------|
| Algeria | 1 | | 1 | |
| Australia | 2 | | | 2 |
| Austria | 8 | 1 | 1 | 6 |
| Belarus | 7 | 4 | 1 | 2 |
| Belgium | 8 | | | 8 |
| Brazil | 5 | | | 5 |
| Bulgaria | 4 | | 1 | 3 |
| Canada | 7 | | | 7 |
| Chile | 1 | | | 1 |
| China, People's Republic of | 16 | 1 | 11 | 4 |
| Cuba | 1 | 1 | | |
| Czech Republic | 5 | | | 5 |
| Denmark | 4 | 1 | 1 | 2 |
| Egypt | 6 | 3 | 3 | |
| Finland | 5 | | | 5 |
| France | 22 | 1 | 1 | 20 |
| Germany | 69 | 2 | 5 | 62 |
| Greece | 6 | | 1 | 5 |
| Hungary | 38 | 2 | 1 | 35 |
| India | 7 | 1 | 4 | 2 |
| Indonesia | 2 | | | 2 |
| Iran (Islamic Republic of) | 4 | 1 | 3 | |
| Iraq | 4 | | 3 | 1 |
| Israel | 1 | 1 | | |
| Italy | 51 | 4 | 8 | 39 |
| Japan | 4 | | | 4 |
| Korea, Republic of | 7 | 3 | | 4 |

| | | | | |
|--------------------------|-----|----|----|-----|
| Lebanon | 3 | | 1 | 2 |
| Luxembourg | 3 | | | 3 |
| Moldova, Republic of | 2 | | 1 | 1 |
| Mongolia | 1 | | | 1 |
| Netherlands | 39 | 4 | 2 | 33 |
| New Zealand | 1 | | | 1 |
| Norway | 14 | | | 14 |
| Poland | 2 | 1 | | 1 |
| Portugal | 13 | | 2 | 11 |
| Qatar | 2 | | | 2 |
| Romania | 9 | 3 | | 6 |
| Russian Federation | 36 | 9 | 8 | 19 |
| Serbia | 2 | | 1 | 1 |
| Slovak Republic | 14 | | 1 | 13 |
| Slovenia | 2 | | 2 | |
| South Africa | 9 | 1 | | 8 |
| Spain | 74 | 2 | | 72 |
| Sweden | 6 | 1 | | 5 |
| Switzerland | 10 | | | 10 |
| Taiwan | 4 | 2 | | 2 |
| Turkey | 5 | | 2 | 3 |
| Ukraine | 17 | | 7 | 10 |
| United Arab Emirates | 1 | | 1 | |
| United Kingdom | 82 | 5 | 3 | 74 |
| United States of America | 10 | 2 | 2 | 6 |
| Uzbekistan | 1 | | 1 | |
| Grand Total | 657 | 56 | 79 | 522 |

Top ten countries


| Country | Accepted | Accepted Withdrawn | No show | Presented |
|-----------------------------|----------|--------------------|---------|-----------|
| United Kingdom | 82 | 5 | 3 | 74 |
| Spain | 74 | 2 | | 72 |
| Germany | 69 | 2 | 5 | 62 |
| Italy | 51 | 4 | 8 | 39 |
| Netherlands | 39 | 4 | 2 | 33 |
| Hungary | 38 | 2 | 1 | 35 |
| Russian Federation | 36 | 9 | 8 | 19 |
| France | 22 | 1 | 1 | 20 |
| Ukraine | 17 | | 7 | 10 |
| China, People's Republic of | 16 | 1 | 11 | 4 |



3. Registration & attendance

3.1 TOTAL ATTENDANCE

| | 2010 | 2012 | 2014 |
|-------------------------------|------------|------------|------------|
| Active delegates (incl Press) | 682 | 866 | 760 |
| Exhibitors | 6 | 45 | 66 |
| Accompanying persons | 12 | N/A | N/A |
| Total | 700 | 911 | 826 |



3.2 BY COUNTRY

| Country | 2010 Berlin | 2012 London | 2014 Barcelona | % of total |
|------------------------------------|----------------|----------------|-------------------|---------------|
| Albania | | | 1 | 0,13% |
| Argentina | 1 | 1 | | 0,00% |
| Australia | 6 | | 3 | 0,40% |
| Austria | 12 | 15 | 10 | 1,32% |
| Azerbaijan | | | 1 | 0,13% |
| Belarus | 1 | 3 | 2 | 0,26% |
| Belgium | 22 | 28 | 16 | 2,12% |
| Bosnia & Herzegovina | 1 | | | 0,00% |
| Brazil | 3 | 6 | 5 | 0,66% |
| Bulgaria | | 4 | 1 | 0,13% |
| Canada | 7 | 3 | 11 | 1,46% |
| Chile | | | 2 | 0,26% |
| China, People's Republic of | 4 | 1 | 2 | 0,26% |
| Colombia | | | 1 | 0,13% |
| Cyprus | | | 2 | 0,26% |
| Czech Republic | 9 | 8 | 7 | 0,93% |
| Denmark | 5 | 9 | 7 | 0,93% |




| | | | | |
|---------------------------------|-----|-----|-----|--------|
| Estonia | 1 | | | 0,00% |
| Egypt | | | 1 | 0,13% |
| Finland | 4 | 11 | 7 | 0,93% |
| France | 20 | 39 | 44 | 5,56% |
| Georgia, Republic of | | | 1 | 0,13% |
| Germany | 162 | 90 | 78 | 10,32% |
| Greece | 78 | 61 | 11 | 1,46% |
| Hungary | 20 | 14 | 36 | 4,76% |
| India | | 1 | | 0,00% |
| Indonesia | 1 | 1 | 3 | 0,40% |
| Iran | 5 | | | 0,00% |
| Israel | 3 | 2 | 3 | 0,40% |
| Italy | 60 | 69 | 60 | 7,94% |
| Japan | 1 | 10 | 7 | 0,93% |
| Korea, Republic of | 3 | 1 | 4 | 0,53% |
| Latvia | 4 | 3 | | 0,00% |
| Lebanon | | | 1 | 0,13% |
| Lithuania | | 1 | 1 | 0,13% |
| Luxembourg | | 4 | 4 | 0,53% |
| Mexico | | | 2 | 0,13% |
| Moldova | | 1 | 1 | 0,13% |
| Mongolia | | | 1 | 0,13% |
| Netherlands | 27 | 67 | 56 | 7,41% |
| New Zealand | | 4 | 1 | 0,13% |
| Nigeria | 2 | | | 0,00% |
| Norway | 15 | 14 | 28 | 3,70% |
| Poland | 14 | 6 | 2 | 0,26% |
| Portugal | 5 | 11 | 19 | 2,51% |
| Qatar | | 1 | 2 | 0,26% |
| Romania | 4 | 2 | 6 | 0,79% |
| Russian Federation | 5 | 24 | 20 | 2,65% |
| Saudi Arabia | 2 | 1 | | 0,00% |
| Serbia | | 2 | | 0,00% |
| Singapore | 1 | | | 0,00% |
| Slovak Republic | 2 | 3 | 13 | 1,72% |
| Slovenia | 1 | | | 0,00% |
| South Africa | 2 | | 7 | 0,93% |
| Spain | 39 | 43 | 94 | 12,30% |
| Sweden | 12 | 17 | 10 | 1,32% |
| Switzerland | 17 | 14 | 17 | 2,25% |
| Taiwan, ROC | 2 | 7 | 2 | 0,26% |
| Thailand | | 4 | | 0,00% |
| Tunisia | | 1 | | 0,00% |
| Turkey | 9 | 1 | 2 | 0,26% |
| Ukraine | | 2 | 7 | 0,93% |
| United Arab Emirates | | | 1 | 0,13% |
| United Kingdom | 62 | 238 | 110 | 14,55% |
| United States of America | 22 | 16 | 26 | 3,44% |
| Uzbekistan | | 1 | | 0,00% |
| Venezuela | 1 | | | 0,00% |
| Vietnam | | | 1 | 0,13% |

3.2.1 Top 10 Countries

| Rank | Country Top 10 | Participants |
|------|--------------------------|--------------|
| 1 | United Kingdom | 110 |
| 2 | Spain | 94 |
| 3 | Germany | 78 |
| 4 | Italy | 60 |
| 5 | Netherlands | 56 |
| 6 | France | 44 |
| 7 | Hungary | 36 |
| 8 | Norway | 28 |
| 9 | United States of America | 26 |
| 10 | Russian Federation | 20 |

3.3 BY REGION

| | 2010 | 2012 | 2014 |
|-------------------------|------------|------------|------------|
| Africa | 4 | 0 | 7 |
| Asia Pacific | 28 | 32 | 27 |
| ESC countries | 616 | 808 | 672 |
| North America | 29 | 19 | 38 |
| South & Central America | 5 | 7 | 8 |
| Total | 682 | 866 | 760 |



4. Industry

4.1 EXHIBITORS

Number of stands:

10 stands of 9m² Miltenyi Biotec, IonOptix, Olink Bioscience, Radnoti Ltd, Aurora Scientific Europe and Transonic, ESC & OUP

Number of exhibitor badges: 66

4.2 EXHIBITION

| Company | 2010 | 2012 | 2014 |
|--------------------------------|-----------|------------|-----------|
| AD Instruments GmbH | 9 | | |
| Athera Biotechnologies AB | | 9 | |
| Aurora Scientific Inc | | 9 | 9 |
| Cairn Research Ltd | | 9 | |
| Data Sciences International | | 9 | |
| European Society of Cardiology | 9 | 9 | 9 |
| IonOptix Europe | 9 | 9 | 9 |
| Moor Instruments | | 9 | |
| Multi Channel Systems | 9 | | |
| Miltenyi Biotec | | | 9 |
| Nanion Technologies | | 9 | |
| Olink Bioscience | | | 9 |
| Oxford University Press | 9 | 9 | 9 |
| PromoCell GmbH | | 9 | |
| Radnoti Ltd | | 9 | 9 |
| Scientifica | | 2 | |
| Seahorse Bioscience | | 9 | |
| Thermo Fisher Scientific | | 9 | |
| Transonic | | | 9 |
| Wisepress Medical Bookshop | | 6 | |
| World Precision Instruments | | 9 | |
| TOTAL | 45 | 134 | 72 |

4.3 SATELLITE SYMPOSIA

A lunch Satellite was organised by Olink Bioscience on Saturday 05 July

4.4 SPONSORSHIP & ADVERTISING

In the main revenue came in the form of Unrestricted Educational Grants (from Industry and Associations) however we also had one physical item sponsored: the badge lanyards.

| Company/Association | Item sponsored |
|--------------------------|---------------------------------|
| Amgen (Europe) GmbH | Badge Lanyards |
| AstraZeneca Farmaceutica | Unrestricted Educational Grants |
| Aurora Scientific | Exhibition Stand Package |
| HFA of the ESC | Unrestricted Educational Grants |
| IonOptix Ltd | Exhibition Stand Package |
| Life Sciences Partners | Unrestricted Educational Grants |

| | |
|---|---------------------------------|
| Miltenyi Biotec GmbH | Exhibition Stand Package |
| Olink Bioscience | Exhibition Stand Package |
| Olink Bioscience | Satellite Symposium |
| OUP/Cardiovascular Research | Unrestricted Educational Grants |
| OUP/cardiovascular Research | Poster awards |
| Radnoti Ltd | Exhibition Stand Package |
| SERVIER INTERNATIONAL | Unrestricted Educational Grants |
| Transonic | Exhibition Stand Package |
| UK Physiological Society | Unrestricted Educational Grants |
| WG on Coronary Pathophysiology and Microcirculation | Unrestricted Educational Grants |
| WG on Thrombosis | Unrestricted Educational Grants |

5. Marketing survey

5.1 FCVB 2014 attendees post congress survey analysis:

This survey was sent to all FCVB congress participants, **580** emails were sent. **103** surveys were completed representing 18% participation. The survey was sent the day after the event.

5.1.1 Delegates' profile


Respondents' profile is one of the most important elements to understand this very specific audience. This is important to offer them the best proposal for FCVB in 2016. The survey focused on demographics: gender, age range, profession and place of work and on the behaviour: Journals and website preferences, number of congresses attended per year, and the element or person who convinced them to attend FCVB 2014.

5.1.2 Delegates demographics

The survey was completed by **46.1%** of men and **53.9%** of women. The repartition here is slightly different from the repartition obtained for other ESC Congresses. The audience is really different; we never had more women than men, based on the answers received.

Breakdown per age range

FCVB participants who answered the questionnaire are younger than the other ESC Congresses. This is the only congress with a larger number of survey respondent under 35 years old, usually the age range most represented is from 36 to 50 years old. This age range represents **31%** of the respondents and a **quarter** of this survey respondents are more than 50 years old.



What's your profession?

Here again, the FCVB audience is really specific as this meeting is focused on Basic Science. FCVB met the target group as more than 80% are Scientists. 11.8% are Cardiologists and 4.9% are cardiologists in training.

What is your place of work?

As for most of the speciality Congresses a majority of respondents works in a University Hospital, for FCVB it represents 62 respondents and 40 in Research. Less than 10 work in a non University hospital, and only 1 respondent works in Private practice.


5.1.3 Delegates' behaviour

To understand their needs, and where they find information, the survey contained an open question about the journals. "Please list two of your favourite professional journals".

| Journals | Answers |
|---|-----------|
| CardioVascular Research | 34 |
| Circulation | 27 |
| Circulation Research | 25 |
| Nature | 11 |
| Arteriosclerosis Thrombosis and Vascular Biology (ATVB) | 9 |
| European Heart Journal | 9 |
| American Journal of Physiology | 5 |
| Journal of Molecular and Cellular Cardiology (JMCC) | 5 |

These figures show that the ESC websites and the ESC Family of journals benefit from good brand awareness as one of the ESC Journal has been cited by 43 out of 103 people. We can see here the other journals the audience read, and where we need to promote the Summer school 2015 and FCVB 2016. Concerning the websites they consult the N°1 is PubMed, ESC website, Google scholar, AHA, Nature with respectively 36, 21, 6, 4 and 4 answers)

Delegates' behaviour can be demonstrated with the attendance frequency: How many congresses this audience attends per year. **91.2%** or the answers attend less than 5 meetings per year and **19.6%** only attend FCVB this year.



Top 3 reasons to attend a congress:

1. The quality and content of the scientific programme
2. To present a research, abstract or poster
3. The different types of sessions

This questionnaire contained also a question regarding the element/ the person which/who convinced them to attend FCVB 2014. The first answer was mentioned by **52.4%** of the respondent is '**Personal decision**'.

This information allows us understand the type of audience, we are in a BtoC context with an individual decision. The other stakeholders are colleagues/managers (mentioned by 32% of the respondent.)


33% through the Website and 12.6% Emailing campaign. In this area the National Cardiac Society does not have a strong impact on the decision making process as it represents 7.8% of the responses.

5.1.4 Delegates' awareness of the Council's activities

The ESC Council on Basic Science is active and proposed:

1. Awards grants to allow young cardiovascular scientists to visit a host institution
2. Proposes funding for a one-year fellowship in Europe
3. Honours independent researchers in the early stage of their career

In this survey we asked respondent if they knew about these activities:




As expected we can see on Graph N°1 that the respondent are more aware about the grants for young Scientists as 67% of respondent answered 'Yes'.

Graph Number 2 and 3 obtained almost the same results with 54% of awareness for the 'funding for one-Year fellowship in Europe' and 56% of awareness for 'Independent researchers in the early stage of their career'.

Half of the audience is aware of these initiatives; we should increase the communication about them.


Have you already benefited from a CBCS travel grant to help you attend ESC Congress?



13% of the respondent have already benefited to the travel grant to attend ESC Congress offered by the Council.

This low figure can be linked to the small number of grants offered compared to the large audience reached at ESC Congress.

Will you register for the Council's Summer School on cardiovascular science next summer 2015?



This educational course aims at Basic scientist, this is the reason why we included this question.

As expected **46%** of the respondent don't know yet. Quite suprisingly, **47%** already know that they won't attend.

This may be due to the date of the summer school which doesn't fit with their calendar. Or maybe they already know they won't have the budget to attend another event in 2015.


These figures show that the Summer school will need an intensive promoiton to obtain a large number of participants.

5.1.5 Delegates' level of satisfaction

The level of satisfaction about the congress is linked to the entire congress experience a delegate receives from the online registration to her/his travel back home. This survey presents the congress experience from a scientific point of view: the topic of interest, then it addresses the overall satisfaction, and the intension to attend again.

Topics of interest


- Developmental biology
- Genetics, Epigenetics and Genomics
- Growth/death, Regeneration and Stem cells
- Signaling
- Ion channels and electrophysiology
- Excitation-contraction coupling, Cardiomyopathy
- Metabolism, Oxygen, Ischaemia and Protection
- Circulation, Vascular biology
- Lipids, Atherosclerosis
- Cytoskeleton
- Integrative mechanisms, Novel diagnostic and Therapeutic approaches



Here in this question the respondent could select one main topic of interest. The proportion is quite mixed with a special focus on Circulation, Vascular Biology, Metabolism, Oxygen, Ischemia and Protection, Growth/death, Regeneration and Stem cells with respectively **17%, 16% and 15%** of the responses.


Then the second group is Lipids, Atherosclerosis, Genetics, Epigenetics and Genomics, Signalling and Excitation-contraction coupling, Cardiomyopathy with **13%, 11%, 8% and 7%** the final group of topics with **5% or less** is: Integrative mechanisms, Novel diagnostic and Therapeutic approaches, Ion channels and electrophysiology, Developmental biology and Cytoskeleton.

Overall level of satisfaction




The highest level of satisfaction concerned Barcelona as destination. (95 Excellent and Good.) The scientific aspect of the congress is the important and recognised by the respondents. The Scientific programme, Posters Quality and session schedule obtained a high level of satisfaction (respectively 90, 89 and 88 responses of good and excellent answers). Council activities and Exhibition are areas to improve.

Please rate your overall congress experience from 0 to 10
(0: very unsatisfied ; 10: very satisfied)



Another way to measure the level of satisfaction is asking them to rate the overall congress from 0 to 10 when 0 is very unsatisfied and 10 very satisfied. Only 2 rates were at 3, the major part of the responses was between 8 and 10 (71 answers out of 103 responses).

87.4% of them said they will recommend FCVB to a colleague that means the high level of satisfaction of the respondents.



Finally, another important way of measuring the level of satisfaction is the intention to attend the congress the following years.

“Are you planning to attend next FCVB in 2016” **47%** of the respondents answered positively.

This FCVB edition seems to have fulfilled respondents expectations enough to make 47% of them planning to attend next year.

Conclusion/ Recommendations:

The FCVB audience is very different from the other ESC Congresses, the respondent are younger, scientist and women. They only attend 1 or 2 congresses per year and decide to attend by them self or thank to a colleague/manager advices based on the scientific programme, their intention to present a paper or the different types of sessions. And Consult mostly ESC journals and Circulation


The Council on Cardiovascular Science need to communicate more on their initiatives as half of the respondent are not aware of the key activities. The council needs to promote the Summer school as more than 45% of the respondent are not planning to attend the event in 2015.

The overall level of satisfaction was high from 57 to 90 of the answers are “Good” and “Excellent” Finally 47% of the respondents plan to attend FCVB 2016 and more than 87% of the respondent recommend their colleagues to attend FCVB.

5.2 Post congress survey to non FCVB attendees analysis:

67 surveys were completed this very low response rate won't be a representative sample, but it give an idea of the results. The survey was sent the after the event here are the results of the questions.

1. Why didn't you attend FCVB Congress this year? (Multiple answers possible)




The key reason for non-attendees respondents to not attend FCVB 2014 was the financial aspect, mentioned by 45% of them.

18 respondents mentioned the schedule conflicts; this is the case for all ESC Congresses. On-site when we discuss with them on the stand or in the corridors, they tell us that they can be on holidays, or their colleagues are and they need to remain at the office. Sometimes they cannot attend a congress because it's not their turn; every year in team member attend a congress and they have to wait for their turn.

This result is encouraging in the way that the scientific programme is not linked to their decision to not attend this year FCVB 2014.


2. How many congresses have you or will you attend this year?



This question is always asked to understand the market FCVB is facing. If a delegate attend a lot of congresses it's easier to convince this delegate to attend FCVB. A delegate attending only 1 or 2 congresses per year will pay more attention in the selection of congresses to attend. The market here is more aggressive.

As expected more than an half only attends 1 or 2 congresses per year. In order to reach a new part of the potential audience of the FCVB, we need to understand: What or who convinced them to attend or not a congress.


3. What/who convince you to attend or not a congress?



The first person in their decision making process is the delegate himself, 63% of the respondent decided not to attend FCVB 2014 by themselves. 25% pick up the information on the website and 24.1% through their National Cardiac Society. This question allows us to understand how important the website is, we need to include content and make sure this is attractive enough to have more delegates. Also the relationship with the National Cardiac Society, to reach a larger audience we need to intense the local promotion and increase the relationship with the basic national groups.

Another key element is to understand the most important factor in their decision to attend a congress.

4. Please rank the following criteria (from the most important:1 to the least important:6) in your decision to attend the congress. Which factor makes you decide to attend a congress?



The most important factor in their decision to attend a congress is for 47 out of 67 respondents the scientific content. The fact a delegate has to present a research is also one of the key elements to have more delegates. The promotion need to be intense about the scientific programme, FCVB needs to increase the number of paper submitted. The 3rd point is to communicate on the attendees profiles. And promote when Key Opinion Leaders in Basic science will be attending FCVB 2016.

5. Please list two of your preferred journal/publication?

| Journal | Answers |
|-------------------------|---------|
| Cardiovascular Research | 17 |
| Circulation | 13 |
| Circulation: Research | 11 |
| JACC | 5 |
| JMCC | 4 |
| Nature | 4 |

This question is always interesting to understand if we use the appropriate tools to promote FCVB. Here we can see that the European Cardiovascular Research journal is the most cited journal, but we can see also the strong presence in the market of American journals such as Circulation and JACC. FCVB 2016 Need to be promoted in these journals.

6. Please list two of your preferred website?

| Website | Answers |
|----------------------|---------|
| PubMed | 11 |
| ESC | 9 |
| AHA | 5 |
| Google | 3 |
| Research Gate | 3 |
| The Heart - Medscape | 2 |

This survey contained the same question for the website. The goal here is to identify where the potential audience as these respondents did not attend FCVB this year, find information.

Next edition will need a strong promotion on these websites.

Finally we asked these non FCVB 2014 attendees if they plan to attend next edition in 2016 in Florence and a 1/3 said they will attend, and 64% said they did know yet. 5% of them already know they won't attend FCVB in 2016.

FRONTIERS IN CARDIOVASCULAR BIOLOGY

Biennial meeting of the ESC Council on Basic Cardiovascular Science

Cardiac
Vascular
Discovery
Translation



FCVB 2016

8-10 July - 2016
Florence Italy

www.escardio.org/FCVB

ESC Working Groups on: Atherosclerosis and Vascular Biology - Cardiac Cellular Electrophysiology - Cellular Biology of the Heart - Coronary Pathophysiology and Microcirculation - Development, Anatomy and Pathology - Myocardial Function - Thrombosis
Sister Societies: European Vascular Biology Organisation - International Society for Heart Research European Section - European Council for Cardiovascular Research - European Society for Microcirculation - European Atherosclerosis Society

